Table 2.
Individual Cohort and Combined Results for Unweighted and Log Odds Ratio-Weighted Type 2 Diabetes Genetic Risk Score in the Breast and Prostate Cancer Cohort Consortiuma
| Cohort | No. in Cohort | No. of Cases | Totalb | Meanc |
GRS |
GRS (-HNF1B)d |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Controls | OR | 95% CI | P Value | OR | 95% CI | P Value | ||||
| Unweighted count | |||||||||||
| ATBC | 1,490 | 245 | 72 | 36.48 | 36.44 | 1.00 | 0.97, 1.04 | 0.894 | 1.00 | 0.97, 1.04 | 0.841 |
| CPSII | 1,258 | 636 | 72 | 37.48 | 37.55 | 1.00 | 0.97, 1.03 | 0.740 | 1.00 | 0.97, 1.03 | 0.839 |
| EPIC | 857 | 431 | 72 | 37.47 | 37.66 | 0.99 | 0.95, 1.02 | 0.460 | 1.00 | 0.96, 1.04 | 0.984 |
| HPFS | 418 | 214 | 72 | 37.70 | 37.47 | 1.02 | 0.97, 1.07 | 0.539 | 1.02 | 0.97, 1.08 | 0.419 |
| MEC | 503 | 244 | 72 | 37.80 | 37.89 | 0.99 | 0.95, 1.04 | 0.779 | 1.00 | 0.96, 1.05 | 0.936 |
| PHS | 553 | 298 | 72 | 37.59 | 37.81 | 0.99 | 0.95, 1.03 | 0.521 | 1.00 | 0.95, 1.04 | 0.800 |
| PLCO | 2,161 | 714 | 72 | 37.36 | 37.64 | 0.98 | 0.96, 1.00 | 0.111 | 0.98 | 0.96, 1.01 | 0.191 |
| Combinede | 7,240 | 2,782 | 72 | 37.42 | 37.31 | 0.99 | 0.98, 1.00 | 0.168 | 1.00 | 0.98, 1.01 | 0.534 |
| Weighted log OR | |||||||||||
| ATBC | 1,490 | 245 | 8.16 | 4.33 | 4.34 | 0.93 | 0.68, 1.29 | 0.675 | 0.94 | 0.68, 1.30 | 0.718 |
| CPSII | 1,258 | 636 | 8.16 | 4.45 | 4.47 | 0.89 | 0.69, 1.14 | 0.358 | 0.90 | 0.70, 1.16 | 0.416 |
| EPIC | 857 | 431 | 8.16 | 4.45 | 4.47 | 0.90 | 0.67, 1.20 | 0.460 | 1.01 | 0.75, 1.36 | 0.961 |
| HPFS | 418 | 214 | 8.16 | 4.49 | 4.46 | 1.11 | 0.73, 1.68 | 0.635 | 1.17 | 0.76, 1.80 | 0.481 |
| MEC | 503 | 244 | 8.16 | 4.49 | 4.54 | 0.78 | 0.53, 1.15 | 0.215 | 0.83 | 0.56, 1.23 | 0.352 |
| PHS | 553 | 298 | 8.16 | 4.45 | 4.52 | 0.76 | 0.53, 1.07 | 0.118 | 0.80 | 0.56, 1.15 | 0.232 |
| PLCO | 2,161 | 714 | 8.16 | 4.43 | 4.49 | 0.74 | 0.61, 0.91 | 0.004 | 0.76 | 0.62, 0.93 | 0.008 |
| Combinede | 7,240 | 2,782 | 8.16 | 4.44 | 4.45 | 0.84 | 0.75, 0.94 | 0.002 | 0.87 | 0.78, 0.97 | 0.015 |
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CI, confidence interval; CPSII, American Cancer Society Cancer Prevention Study II Nutrition Cohort; EPIC, European Prospective Investigation into Cancer and Nutrition; GRS, genetic risk score; HPFS, Health Professionals Follow-up Study; MEC, Multiethnic Cohort Study; OR, odds ratio; PCa, prostate cancer; PHS, Physicians' Health Study; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; T2D, type 2 diabetes.
a Logistic regression models were used to regress GRS on risk of PCa.
b Total indicates the maximum bound for the respective GRS, with a value close to this total indicating high genetic predisposition for T2D.
c Mean GRS was calculated for PCa cases and PCa controls.
d HNF1B was excluded from the GRS and included as a separate covariate.
e For combined estimates, cohort indicators were added to adjust for cohort effects.